Search Results
The product title you are looking for is no longer available. Other similar products that may interest you are listed below:
|
Results for 'Chipscreen Biosciences Ltd -Company Report' |
|
|
| Title | Publication Date | Price | Relevance |
|---|---|---|---|
| Chipscreen Biosciences Ltd-Therapeutic Competitors Report | Mar 2011 | £220 | 100% |
| Chipscreen Biosciences Ltd - Product Pipeline Review Q1 2011 |
May 2011 | £315 | 99% |
| Cutaneous T-Cell Lymphoma - Pipeline Review H2 2011 |
Aug 2011 | £315 | 64% |
| Diffuse Large B-Cell Lymphoma - Pipeline Review H1 2012 |
Jan 2012 | £325 | 63% |
| B-Cell Lymphomas - Pipeline Review H1 2012 |
Jan 2012 | £325 | 62% |
| Non-Small Cell Lung Cancer - Pipeline Review H2 2011 |
Sep 2011 | £315 | 59% |
| T-Cell Lymphomas - Pipeline Review Q2 2011 |
Apr 2011 | £315 | 59% |
| Diabetes - Pipeline Review H2 2011 |
Oct 2011 | £315 | 58% |
| Lymphoma - Pipeline Review Q3 2011 |
Jul 2011 | £315 | 58% |
| Breast Cancer - Pipeline Review Q3 2011 |
Jul 2011 | £315 | 57% |
| Non-Hodgkin Lymphoma - Pipeline Review H2 2011 |
Sep 2011 | £315 | 57% |
| Diabetes Drug Pipeline Competitor Analysis |
Nov 2008 | £995 | 53% |
| Type 2 Diabetes - Pipeline Review H2 2011 |
Sep 2011 | £315 | 52% |
- Results 1 - 13 of 13
-
-
- 1
-
-
